Is IBIO or IDYA more undervalued in 2026?

CirclFi compares iBio, Inc. (IBIO) and IDEAYA Biosciences, Inc. (IDYA) using 13 institutional-grade valuation models. IBIO has a Quality of Company score of 3.6/10 while IDYA scores 6.4/10.

Which is a better buy — IBIO or IDYA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do IBIO and IDYA valuations compare?

IBIO at $1.90 and IDYA at $29.47 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

IBIO vs IDYA Valuation Comparison 2026 — Intrinsic Value Analysis

IBIO

Pharmaceutical Preparations

iBio, Inc.

Quality

3.6

out of 10

Value Trap

SAFE

Price

$1.90

Last close

Models

10/13

Active

IDYA

Pharmaceutical Preparations

IDEAYA Biosciences, Inc.

Quality

6.4

out of 10

Value Trap

SAFE

Price

$29.47

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	IBIO Fair Value	IBIO Upside	IDYA Fair Value	IDYA Upside
Bayesian DCF	Intrinsic	$0.99	-47.8%	$7.23	-75.5%
Earnings Power Value	Intrinsic	—	—	$16.44	-46.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.08	-43.1%	$9.32	-68.4%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for IBIO vs IDYA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IBIO vs IDYA — Which Stock Is More Undervalued?

IDYA scores higher with a 6.4/10 quality rating vs IBIO's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing iBio, Inc. (IBIO) and IDEAYA Biosciences, Inc. (IDYA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IBIO currently trades at $1.90 with a QOC of 3.6/10, while IDYA trades at $29.47 with a QOC of 6.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).